# Maintenance of Benefit With Atomoxetine Hydrochloride in Adolescents With ADHD

> **NCT00191035** · PHASE4 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 520 (—)

## Conditions studied

- Attention-Deficit/Hyperactivity Disorder

## Interventions

- **DRUG:** Atomoxetine

## Key facts

- **NCT ID:** NCT00191035
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** —
- **Final completion:** 2006-11
- **Target enrollment:** 520 (—)
- **Last updated:** 2006-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00191035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00191035, "Maintenance of Benefit With Atomoxetine Hydrochloride in Adolescents With ADHD". Retrieved via MORVS 2026-10-22 from https://api.morvs.ai/clinical/NCT00191035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*